Posterior Segment

This year, we are celebrating our inaugural touchOPHTHALMOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform ophthalmology in the years to come.

In this Q&A, Dr Cicinelli shares her inspirations, career journey and insights into the future of ophthalmology and where she plans to make her mark.

In this Q&A, she shares insights into her career journey, the latest innovations shaping the field and her vision for the future of ophthalmology.

In this Q&A, he shares insights into his career, research interests and the evolving landscape of ophthalmic care.

4D Molecular Therapeutics, a clinical-stage genetic medicines company, has announced promising topline interim results from Part 1 of the SPECTRA clinical trial evaluating 4D-150, a novel treatment for diabetic macular edema (DME).

The American Academy of Ophthalmology (AAO) 2024 meeting in Chicago showcased many advancements in retinal research that show promise for the future.

The EURETINA 2024 Congress, held in Barcelona from September 19-22, brought together leading experts in ophthalmology to share the latest research and innovative treatments for retinal diseases. Among the highlights were several late-breaking abstracts that showcased promising advances in therapeutics for conditions such as retinopathy of prematurity (ROP), diabetic retinopathy (DR) and  age-related macular degeneration (AMD). These studies not only demonstrated the efficacy and safety of novel treatment options but also addressed critical unmet needs in reducing patient burden and improving long-term outcomes.

The European Society of Cataract and Refractive Surgeons (ESCRS) is gearing up for its 42nd Congress, scheduled to take place from September 6-10, 2024, at the Fira de Barcelona in Spain. This prestigious event promises to be a hub of innovation and knowledge-sharing in ophthalmology.